Cannabis Use Disorder May Up Risk of Benign Salivary Gland Tumors
By Elana Gotkine HealthDay Reporter
MONDAY, July 21, 2025 -- Cannabis use disorder (CUD) is associated with increased risk of benign salivary gland tumors, according to a research letter published online July 17 in JAMA Otolaryngology-Head & Neck Surgery.
Tyler J. Gallagher, M.D., M.P.H., from the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues conducted a retrospective cohort study using deidentified data from the TriNetX U.S. Collaborative Network to examine the association between cannabis use and benign salivary gland tumors. Two cohorts of adults age 18 years or older were created: one had a diagnosis of cannabis-related disorder and the other had no cannabis-related disorder diagnosis between Jan. 24, 2005, and Jan. 24, 2025.
The researchers found that the incidence of any benign major salivary gland tumor was higher in the group with CUD (183,818 individuals) than the group without CUD (6,248,964 individuals) (0.08 versus 0.02 percent). The group with versus without CUD also had higher incidence of benign parotid salivary gland tumors (0.05 versus 0.01 percent). After propensity score matching, the relative risk of any benign major salivary gland tumor was higher among those with versus without CUD at all time points (relative risks, 5.18, 4.32, and 5.00 at any time, zero to less than five years, and at five or more years, respectively) after CUD diagnosis or outpatient hospital visit. Elevated relative risk of a benign parotid salivary gland tumor was also seen (relative risks, 5.16, 4.92, and 3.90 for any time, zero to less than five years, and five or more years, respectively).
"The elevated relative risk of benign parotid tumors and the persistent association over time highlight potential site-specific outcomes of cannabis use," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus...
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care...
Most People With Cannabis Use Disorder Remain Untreated
MONDAY, June 9, 2025 -- Most individuals in the United States with cannabis use disorder (CUD) do not receive treatment, according to a study published online May 19...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.